1. Human Fascioliasis in Rhodesia. Journal of Tropical Medicine and Hygiene 1972; 75: 221-223. Perry W, Goldsmith JM and Gelfand M.
  2. Emetine and Cyclophosphamide in Carcinoma of the Lung. Lancet 1972; 2: 427. Hyde KR, Marsh K, Perry W. (Letter).
  3. Peritoneal Tuberculosis Presenting as Pyrexia of Unknown Origin in Immigrants.     Journal of Tropical Medicine and Hygiene 1976; 79: 83-88. Perry W and McKerron CG.
  4. Vitamin D Resistance in Osteomalacia FollowingUretero-Sigmoidostomy. New England Journal of Medicine 1977; 279: 1110-1112. Perry W, Allen LN, Stamp TCB and Walker PG.
  5. Hereditary Hypophosphataemic Rickets with Autosomal Recessive Inheritance and Severe Osteosclerosis. Journal of Bone and Joint Surgery 1978; 60: 430-434. Perry W and Stamp TCB.
  6. Metabolic Effects of Enzyme Induction and Inhibition by Rifampicin and Isoniazid. Essay awarded the Seddon Gold Medal and Prize, Royal National Orthopaedic Hospital and Institute of Orthopaedics University of London 1978. Perry W. See refs 7, 15, 21, 24, 25, 26, 27)
  7. Elevation of Plasma Levels of Lysosomal Enzymes during Treatment with Rifampicin and Isoniazid. Biochemical Medicine 1978; 20: 153-159. Perry W, Jenkins MV, Stamp TCB.
  8. Induction and Inhibition of Hepatic Microsomal Enzymes by Rifampicin and Isoniazid. Clinical Science and Molecular Medicine 1978; 55: 1-2P. Perry W, Jenkins MV, Erooga MA, Setchell KDR and Stamp TCB.
  9. Treatment of Privational Late Rickets and Osteomalacia with the Vitamins D. In Vitamin D Basic Research and its Clinical. Application Walter de Gryer and Company, Berlin, New York 1979; 1153-1162. Stamp TCB, Perry W, MacArthur S and Jenkins MV.
  10. Treatment of Bone and Joint Tuberculosis. In Rifampicin in Extra-Pulmonary Tuberculosis Royal Society of Medicine International Congress and Symposium No. 11. Academic Press Inc (London) and the Royal Society of Medicine 1979; 19-27. Perry W.
  11. Lysosomal Enzymes and Pancreatitis During Rifampicin Therapy. Lancet 1979; 1: 492. Perry W, Jenkins MV and Stamp TCB (Letter).
  12. Treatment of Hypophosphataemic Tumour Osteomalacia and of Hyperphosphataemic Tumoural Calcinosis. 4th International Workshop on Phosphate and Other Minerals, Strasburg, France, 1979. Stamp TCB, Perry W, Jenkins MV and Parsons JA.
  13. Male Infertility. Al-Faisal Medical Journal No. 2, November 1980; 8-11. (Published at King Faisal University, Dammam, Saudi Arabia). Perry W.
  14. Nutritional Osteomalacia and Late Rickets in Greater London 1974-1979: Clinical and Metabolic Studies in 45 Patients. Clinics in Endocrinology and Metabolism 1980; Vol. 9: No. 1, 81-105. Stamp TCB, Walker PG, Perry W and Jenkins MV.
  15. Isoniazid Inhibition of Rifampicin-Mediated Enzyme Induction. Saudi Medical Journal 1981; 2: 67-71. Perry W.
  16. Value of Serum Gonadotrophin and Testicular Biopsy in the Aetiology of Azoospermia: Report of Three Illustrative Cases and Review of the Problem. 6th Saudi Medical Conference Jeddah, Saudi Arabia, 1981. Perry W, Kubba A and Lautsch EV.
  17. Clinico-Pathological Appraisal of Male Infertility in Saudi Arabia. 6th Saudi Medical Conference, Jeddah., Saudi Arabia, 1981. Kubba A, Lautsch EV and Perry W. (Not included).
  18. Calcium Metabolism During Rifampicin and Isoniazid Therapy for Tuberculosis. Journal of the Royal Society of Medicine 1982; 75: 533-536. Perry W, Erooga MA, Brown J and Stamp TCB.
  19. Metabolic Consequences of Rifampicin-Mediated Enzyme Induction during treatment for Tuberculosis. Current Chemotherapy and Immunotherapy Proc 12th International Congress of Chemotherapy 1982. Vol. 2, 987-990. Perry W, Jenkins MW, Brown J, Erooga MA, Setchell KDR and Stamp TCB.
  20. Endocrine Assessment of the Subfertile Male in Saudi Arabia. 7th Saudi Medical Conference, King Faisal University, Dammam, Saudi Arabia 1983; 145-149. Perry W.
  21. Calcium Metabolism During Rifampicin and Isoniazid Therapy. Tubercle 1983;64: 57- 58. Perry W. (Letter).
  22. Calcium Metabolism During Rifampicin and Isoniazid Therapy. Journal of the Royal Society of Medicine 1983; 76: 326-327. Perry W. (Letter).
  23. Case of Situs Inversus and Embryonic Ovarian Carcinoma. Gynaecologic Oncology 1984; 18: 270-273. Ibrahim EM, Al Farag A, Al Tamimi D and Perry W.
  24. Studies of Urinary D-Glucaric Acid Excretion During Rifampicin Isoniazid and Anticonvulsant Enzyme Induction. Clinical Pharmacology and Therapeutics 1984; 35: 710-715. Perry W and Stamp TCB.
  25. Hepatic Mixed Function Oxidase Activity During Rifampicinilsoniazid Therapy in Indian Vegetarians. International Journal of Clinical Pharmacology, Therapeutics and Toxicology 1986; 24: 344-348. Perry W and Jenkins MV.
  26. Note on the Enzyme Assay for Urinary D-Glucaric Acid and Correlation with Rifampicin Induced Mixed Function Oxidase Activity. International Journal of Clinical Pharmacology, Therapeutics and Toxicology 1986; 24: 609-613. Perry W and Jenkins MV.
  27. Plasma Gamma Glutamyltranspeptidase during Rifampicin Treatment for Tuberculosis. International Journal of Clinical Pharmacology, Therapeutics and Toxicology, 1987; 25: 7-9. Perry W and Jenkins MV.
  28. Rifampicin, Glucose and Halothane as Mediators of Lysosomal Enzyme Induction. Medical Hypotheses, 1988; 26: 131-134. Perry W.
  29. Value of EDTA in Atherosclerosis. The Royal College of General Practitioners 1988; Members Book 213-214. Perry W.
  30. Osteoporosis: Prevention, Detection, Treatment. EDC: Update Series 1989. Mortimer CH and Perry W. (Personal publication).
  31. Skeletal Effects of Oestrogen and Testosterone in Postmenopausal Women. British Medical Journal 1988; 297: 6870688. Mortimer CH and Perry W. (Letter).
  32. EDC Newsletter: March 1989. sHRT and osteopenia overdosing on oestrogen? Mortimer CH and Perry W. (Personal publication).
  33. EDC Newsletter: June 1989. Osteoporosis Screening: An Essential Part of Gynaecological Assessment. Mortimer CH and Perry W. (Personal publication).
  34. EDC Newsletter: November 1989. Osteoporosis Evaluation: Secondary Causes Common. Mortimer CH and Perry W. (Personal publication).
  35. Bone Density Screening for Osteoporosis. Lancet 1990; 336: 502-503. Andersson MI, Mortimer CH and Perry W. (Letter).
  36. Bone Density Screening for Osteoporosis. Lancet 1990; 336:1133-1134. Andersson Ml, Mortimer CH and Perry W. (Letter).
  37. Effect of Methylcysteine on Lipoprotein ‘a’ Levels. Pilot Study. Report submitted to Sinclair Pharmaceuticals, Godalming, Surrey. October 1992.
  38. Osteoporosis Screening in a Largely Self-Referred Population: High Prevalence But Low Medical Priority. Why? Mineral and Electrolyte Metabolism 1994; 20: 287-293. Perry W, Andersson MI and Mortimer CH.
  39. Primary Hyperparathyroidism and Vitamin D Deficiency. Clinical Endocrinology 1995; 43: 130. Perry W. (Letter).
  40. Measurement of Bone Density in Osteoporosis. British Medical Journal 1995; 311: 952. Perry W. (Letter).
  41. Ability of bone mineral density to predict osteoporotic fractures: Case for screening exists. British Medical Journal 1996; 313: 561. Perry W. (Letter).
  42. Bone mineral density measurement. Journal of Royal Society of Medicine. 1996; 89: 599. Perry W. (Letter).
  43. Osteoporosis management. Prescribers Journal. 1997; 37: No, 4: 250. Perry W. (Letter).
  44. Combined oral oestradiol valerate-norethisterone treatment over three years in postmenopsausal women. 1. Clinical aspects and endometrial histology. Gynaecological Endocrinology. 1998; 12: 109-122. Perry W, Wiseman R, Cullen NM.
  45. Combined oral oestradiol valerate-norethisterone treatment over three years in postmenopausal women. Correlation between oestrogen levels and bone mineral density sites. Perry W, Wiseman R.A. British Journal of Obstetrics and Gynaecology. 2000; 107: 1401-1406.
  46. The effect on climacteric symptoms of oestrogen replacement therapy with a novel
    oestradiol acetate intravaginal ring in post-menopausal women. Buckler H, Perry W. British Menopause Society Meeting. June 28-29th 2001.
  47. Comparison of a novel intravaginal ring delivering oestradiol valerate vs oral oestradiol for vasomotor symptom relief in postmenopausal women. Al-Azzawi F, Sarni S, Wahab M, Perry W, Buckler H. British Menopause Society Meeting. June 28-29th 2001.
  48. Combined oral oestradiol valerate-norethisterone treatment over three years in post- menopausal women. Effect on lipids, coagulation factors, haematology and biochemistry. Perry W, Wiseman RA. Maturitas 2002. 42: 157-164.
  49. Cardiac cartography. Submitted to BMJ July 2004. (Under revision).
  50. Clinical Trial Studies.

13. Male Infertility.

Al-Faisal Medical Journal No. 2, November 1980; 8-11. (Published at King Faisal University, Dammam, Saudi Arabia). Perry W.

Click here to open PDF.

50. CLINICAL TRIAL STUDIES (As Principal or Co-investigator) 1989 – 2001

Click to here open PDF file or text is below.

  1. Open label study of continuous oestrogen and progesterone (oestradiol valerate 2mg and norethisterone 0.7mg) single centre study. 206 patients between 1991 and 1994. Climesse marketed 1996. Principal investigator. Objective: no bleed hormone replacement. (Novartis) See refs 44, 45, 48.
  2. Open label study daily oestrogen and quarterly progesterone using oestradiol valerate 2mg and levonorgestrol 75ug called Nuvelle 3. 120 patients single centre between 1993-1995. Objective: quarterly bleed hormone replacement. Co-investigator. Study completed. Outcome: endometrial abnormalities, not marketed. (Schering).
  3. Open label study with continuous oestrogen and progesterone using 17beta-oestradiol 2mg and norethisterone acetate lmg called Primelle. 150 patients, multi-centre study 1994-­1995. Co-investigator. Objective: no bleed hormone replacement. Completed study, – marketed, (Schering) Nuvelle continuous.
  4. Open label study, continuous oral oestrogen 17beta-oestradiol and quarterly
    progesterone norethisterone acetate lmg called Tribeta. 225 patients 1995-1998. Single centre study. Co-investigator. Objective: quarterly bleed HRT. Study completed: outcome unknown. (Schering).
  5. Open label randomised multi-centre study. Progestasert (intra-uterine device) vs norethisterone orally 1 mg with oral 17beta-oestradiol 2mg continuously to all patients. 228 patients. Co-investigator. A no bleed HRT study but discontinued half way through due to unacceptable bleeding patterns. (Astra Zeneca).
  6. Open randomised dose-ranging comparator control parallel group study. Comparing test drug 17beta-oestradiol lmg with natural progesterone 25mg or 50mg (Scheresol) against Premique 0.625mg of conjugated equine oestrogen and 5mg medroxyprogesterone acetate. No bleed HRT. 150 patients. Co-investigator. Study completed. Outcome: not marketed. (Wyeth).
  7. Six month open label comparative study of two 7 day patches (Cygnus 13.5 and 27 cm2) vs Climara (12.5cm2) in postmenopausal women – symptoms and endometrial histology. Multi-centre study. 420 patients. Co-investigator. Study completed. Outcome: not known. (Wyeth).
  8. Double-blind multi-centre randomised comparator controlled trial in postmenopausal women to investigate effect of intra vaginal ring device releasing 17beta-oestradiol compared to oral oestradiol on symptoms of lipid metabolism and BMD. 132 patients. Principal investigator at Endocrine Centre and currently continuing. Completed February 2000. Marketed as Menoring 50, July 2001. (Galen). See refs 46, 47.
  9. Phase II multi-centre double-blind placebo controlled parallel group study to observe a topical product (P45 cream) on treatment of alopecia androgenetica. Investigator for Blossom Inn Medical Centre on behalf of the Endocrine Centre. 70 patients. Current trial. Completed September 2000. Outcome – further trial.